Liquidia (NASDAQ:LQDA) Price Target Raised to $44.00 at Wells Fargo & Company

Liquidia (NASDAQ:LQDA) had its price target increased by equities researchers at Wells Fargo & Company from $31.00 to $44.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target points to a potential upside of 28.50% from the company’s current price.

Other analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research report on Thursday, January 22nd. HC Wainwright upped their price target on Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday. Zacks Research lowered shares of Liquidia from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 27th. Needham & Company LLC boosted their price objective on shares of Liquidia from $52.00 to $54.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Jefferies Financial Group upped their price objective on shares of Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.00.

Liquidia Trading Down 0.8%

Shares of Liquidia stock opened at $34.24 on Friday. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. The company has a market capitalization of $2.98 billion, a P/E ratio of -23.78, a PEG ratio of 0.60 and a beta of 0.52. Liquidia has a 1 year low of $11.26 and a 1 year high of $46.67. The company’s fifty day moving average is $37.07 and its two-hundred day moving average is $30.84.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.18). Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The business had revenue of $92.02 million for the quarter. Liquidia’s quarterly revenue was up 3072.4% on a year-over-year basis. Analysts forecast that Liquidia will post -1.51 earnings per share for the current year.

Insiders Place Their Bets

In other Liquidia news, General Counsel Russell Schundler sold 27,289 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,021,427.27. Following the completion of the transaction, the general counsel directly owned 579,394 shares of the company’s stock, valued at approximately $21,686,717.42. This trade represents a 4.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Michael Kaseta sold 36,932 shares of Liquidia stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $1,382,364.76. Following the sale, the chief financial officer owned 350,919 shares of the company’s stock, valued at approximately $13,134,898.17. The trade was a 9.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 212,534 shares of company stock worth $7,964,719. Insiders own 26.50% of the company’s stock.

Institutional Trading of Liquidia

A number of institutional investors have recently bought and sold shares of the company. Farallon Capital Management LLC increased its position in shares of Liquidia by 1.1% in the fourth quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock valued at $298,547,000 after buying an additional 90,400 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Liquidia by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock worth $138,439,000 after buying an additional 52,671 shares in the last quarter. Opaleye Management Inc. grew its stake in Liquidia by 9.5% in the 2nd quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock valued at $30,838,000 after acquiring an additional 215,000 shares during the last quarter. Caprock Group LLC grew its stake in Liquidia by 9.3% in the 4th quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock valued at $61,527,000 after acquiring an additional 151,832 shares during the last quarter. Finally, TCG Crossover Management LLC purchased a new position in Liquidia during the 3rd quarter valued at about $38,887,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: HC Wainwright raised its price target to $55 and maintained a Buy rating, reflecting aggressive upside and materially higher longer?term EPS forecasts that support a higher valuation. HC Wainwright PT Raise
• Positive Sentiment: Needham and BTIG also bumped price targets (Needham to $54, BTIG to $50) and keep Buy ratings — consistent multi?broker upgrades amplify buying interest from growth/healthcare investors. Needham PT Raise
• Positive Sentiment: Company reported strong YUTREPIA® adoption: $148.3M FY2025 product sales, $90.1M in Q4, over 3,600 prescriptions and the second consecutive profitable quarter with $190.7M cash — fundamentals that support higher forward earnings expectations. Company Results & Release
• Neutral Sentiment: Quarterly EPS headlines are mixed: Liquidia reported $0.15 EPS (reported by the company), which beat some low-model estimates but missed a higher consensus ($0.33) cited by other services — this divergence produced intraday volatility as investors reconcile differing expectations. Earnings Coverage
• Negative Sentiment: Shares gapped down in early trading after the earnings release amid headlines calling the quarter “weak” relative to some expectations — that initial sell?off pressured the stock despite the stronger underlying sales and cash metrics. Gap Down Coverage
• Negative Sentiment: Notable insider and institutional selling has been reported (including a recent ~$5.1M manager sale), which may cap upside and concern short?term investors about supply pressure. Insider/Manager Sale

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).